Candel Therapeutics (CADL) Gains from Investment Securities (2020 - 2023)
Historic Gains from Investment Securities for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $483000.0.
- Candel Therapeutics' Gains from Investment Securities rose 11760.2% to $483000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$3.0 million, marking a year-over-year increase of 3425.8%. This contributed to the annual value of $20.8 million for FY2024, which is 225341.61% up from last year.
- Per Candel Therapeutics' latest filing, its Gains from Investment Securities stood at $483000.0 for Q4 2023, which was up 11760.2% from -$581000.0 recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' Gains from Investment Securities ranged from a high of $12.4 million in Q2 2021 and a low of -$9.2 million during Q4 2021
- For the 4-year period, Candel Therapeutics' Gains from Investment Securities averaged around $1.5 million, with its median value being $483000.0 (2023).
- Within the past 5 years, the most significant YoY rise in Candel Therapeutics' Gains from Investment Securities was 1608907.93% (2021), while the steepest drop was 30331.56% (2021).
- Over the past 4 years, Candel Therapeutics' Gains from Investment Securities (Quarter) stood at $4.5 million in 2020, then crashed by 303.32% to -$9.2 million in 2021, then skyrocketed by 70.17% to -$2.7 million in 2022, then surged by 117.6% to $483000.0 in 2023.
- Its last three reported values are $483000.0 in Q4 2023, -$581000.0 for Q3 2023, and -$144000.0 during Q2 2023.